Literature DB >> 22699835

Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis.

Asim Maqbool1, Joan I Schall, Paul R Gallagher, Babette S Zemel, Birgitta Strandvik, Virginia A Stallings.   

Abstract

BACKGROUND AND
OBJECTIVE: Children with cystic fibrosis (CF) and pancreatic insufficiency (PI) are at risk for fatty acid (FA) abnormalities and essential FA deficiency, with low linoleic acid (LA) and docosahexaenoic acid (DHA) concentrations and abnormal triene:tetraene (T:T) and arachidonic acid (AA):DHA ratios. The aim of the article was to determine whether type of dietary fat predicted serum LA, DHA, T:T, and AA:DHA ratios in subjects with CF and PI as compared to an unaffected comparison group.
METHODS: Serum FA concentrations were assessed by capillary gas-liquid chromatography (mol%) and dietary intake by 7-day weighed food records; the 3-day coefficient of fat absorption was calculated. Total energy intake was expressed in kilocalories.
RESULTS: A total of 65 subjects with CF and PI (8.4 ± 1.0 years, 32 girls) and 22 controls (8.5 ± 1.1 years, 13 girls) were included. Despite greater energy, saturated fat, and LA intake, the subjects with CF had lower serum LA and DHA and higher T:T and AA:DHA than those in the comparison group. Dietary total fat, monounsaturated fatty acid (MUFA), polyunsaturated fatty acid (PUFA), LA, total ω 6 polyunsaturated fatty acid (Tω6PUFA), and α-linolenic acid (ALA) intake positively predicted serum LA concentration. MUFA, total ω 3 polyunsaturated fatty acid (Tω3PUFA), and ALA intake positively predicted serum DHA concentration. Total dietary fat, MUFA, PUFA, Tω3PUFA, LA, and ALA intake negatively predicted serum T:T. ALA and Tω3PUFA intake negatively predicted serum AA:DHA.
CONCLUSIONS: Dietary fat patterns influenced serum LA, DHA, T:T, and AA:DHA in children with CF and PI. These data suggest that changes in dietary practices may result in FA profiles associated with improved clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699835      PMCID: PMC4699309          DOI: 10.1097/MPG.0b013e3182618f33

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  41 in total

1.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

Review 2.  Omega-3 fatty acids for cystic fibrosis.

Authors:  Colleen Oliver; Nikki Jahnke
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

3.  Polyunsaturated fatty acids in cystic fibrosis are related to nutrition and clinical expression of the disease.

Authors:  Jaroslaw Walkowiak; Aleksandra Lisowska; Michal Blaszczynski; Juliusz Przyslawski; Mieczyslaw Walczak
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-10       Impact factor: 2.839

4.  Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: are they related to clinical outcomes?

Authors:  Carla Colombo; Veronica Bennato; Diana Costantini; Lauretta Valmarana; Valeria Daccò; Laura Zazzeron; Diana Ghisleni; Maria Grazia Bruzzese; Silvia Scaglioni; Enrica Riva; Carlo Agostoni
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-11       Impact factor: 2.839

Review 5.  An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis.

Authors:  Thierry Charles Coste; Martine Armand; Jean Lebacq; Patrick Lebecque; Pierre Wallemacq; Teresinha Leal
Journal:  Clin Biochem       Date:  2007-01-19       Impact factor: 3.281

6.  Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; J Felipe Garcia-Espana; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

7.  Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients.

Authors:  S Van Biervliet; M Devos; T Delhaye; J P Van Biervliet; E Robberecht; A Christophe
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2008-02-13       Impact factor: 4.006

Review 8.  alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans.

Authors:  J Thomas Brenna; Norman Salem; Andrew J Sinclair; Stephen C Cunnane
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-03-09       Impact factor: 4.006

Review 9.  Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements.

Authors:  Mélanie Plourde; Stephen C Cunnane
Journal:  Appl Physiol Nutr Metab       Date:  2007-08       Impact factor: 2.665

10.  Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis.

Authors:  Gabriel Olveira; Casilda Olveira; Eva Acosta; Francisco Espíldora; Lourdes Garrido-Sánchez; Eva García-Escobar; Gemma Rojo-Martínez; Montserrat Gonzalo; Federico Soriguer
Journal:  Arch Bronconeumol       Date:  2009-12-31       Impact factor: 4.872

View more
  13 in total

1.  Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.

Authors:  Scott D Sagel; Brandie D Wagner; Assem Ziady; Tom Kelley; John P Clancy; Monica Narvaez-Rivas; Joseph Pilewski; Elizabeth Joseloff; Wei Sha; Leila Zelnick; Kenneth D R Setchell; Sonya L Heltshe; Marianne S Muhlebach
Journal:  J Cyst Fibros       Date:  2019-12-20       Impact factor: 5.482

2.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

3.  The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study.

Authors:  Michael Glenn O'Connor; Adam Seegmiller
Journal:  J Cyst Fibros       Date:  2016-07-26       Impact factor: 5.482

4.  Choline Supplementation With a Structured Lipid in Children With Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Joan I Schall; Maria R Mascarenhas; Asim Maqbool; Kelly A Dougherty; Okan Elci; Dah-Jyuu Wang; Talissa A Altes; Kevin A Hommel; Walter Shaw; Jeff Moore; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-04       Impact factor: 2.839

Review 5.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

6.  Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study.

Authors:  Michael Glenn O'Connor; Kelly Thomsen; Rebekah F Brown; Michael Laposata; Adam Seegmiller
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2016-08-27       Impact factor: 4.006

Review 7.  Role for animal models in understanding essential fatty acid deficiency in cystic fibrosis.

Authors:  Deanne H Hryciw; Courtney A Jackson; Nirajan Shrestha; David Parsons; Martin Donnelley; Andrew J McAinch
Journal:  Cell Mol Life Sci       Date:  2021-11-05       Impact factor: 9.261

8.  Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline.

Authors:  Catherine M McDonald; Jessica A Alvarez; Julianna Bailey; Ellen K Bowser; Kristen Farnham; Mark Mangus; Laura Padula; Kathleen Porco; Mary Rozga
Journal:  J Acad Nutr Diet       Date:  2020-06-19       Impact factor: 5.234

9.  Reference values of whole-blood fatty acids by age and sex from European children aged 3-8 years.

Authors:  M Wolters; H Schlenz; R Foraita; C Galli; P Risé; L A Moreno; D Molnár; P Russo; T Veidebaum; M Tornaritis; K Vyncke; G Eiben; L Iacoviello; W Ahrens
Journal:  Int J Obes (Lond)       Date:  2014-09       Impact factor: 5.095

10.  Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral Feeding.

Authors:  John Stevens; Colby Wyatt; Perry Brown; Dhiren Patel; Danica Grujic; Steven D Freedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-10       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.